Industry Insights: Regulatory milestones, high-volume dealmaking, and ASCO data readouts signal a landmark month for bioconjugates
Bioconjugate Insights · 02.07.2026 · 1 (4) · 185–201
DOI: 10.18609/bci.2026.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Insights, online erschienen am 02.07.2026. Verfasst von Lauren Coyle. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
June brought an active month for the bioconjugate field, with a dense cluster of regulatory approvals, high-volume dealmaking, and an expansive ASCO Annual Meeting serving as the month’s central platform for clinical data disclosure. Regulatory highlights spanned multiple geographies and ADC formats: the US FDA approved pivekimab sunirine-pvzy for BPDCN and datopotamab deruxtecan for first-line metastatic TNBC, and granted two new indications for trastuzumab deruxtecan in early HER2-positive breast cancer. The EMA’s CHMP issued positive opinions for sacituzumab govitecan in first-line TNBC and enfortumab vedotin plus pembrolizumab as perioperative treatment in muscle-invasive bladder cancer. In China, NMPA approvals were received for tisotumab vedotin in cervical cancer and disitamab vedotin plus toripalimab in urothelial carcinoma, while Innovent Biologics submitted the first CLDN18.2-targeting ADC for regulatory review globally. The US FDA also issued a draft guidance proposing streamlined nonclinical safety requirements for conjugated oncology products, a development with broad implications for ADC development timelines.
Zitieren
APA
Coyle, L. (2026). Industry Insights: Regulatory milestones, high-volume dealmaking, and ASCO data readouts signal a landmark month for bioconjugates. Bioconjugate Insights, 1(4), 185–201. https://doi.org/10.18609/bci.2026.023
Vancouver
Coyle L. Industry Insights: Regulatory milestones, high-volume dealmaking, and ASCO data readouts signal a landmark month for bioconjugates. Bioconjugate Insights. 2026;1(4):185–201. doi:10.18609/bci.2026.023
BibTeX
@article{Coyle2026,
author = {Coyle, Lauren},
title = {Industry Insights: Regulatory milestones, high-volume dealmaking, and ASCO data readouts signal a landmark month for bioconjugates},
journal = {Bioconjugate Insights},
year = {2026},
volume = {1},
number = {4},
pages = {185–201},
doi = {10.18609/bci.2026.023}
}
EUVIMED